Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the ...

Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression ...

Patients in Scotland with relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment can now access ...